Tablet Presentation

Each Film Coated Tablet Contains:
Lornoxicam IP 8 mg
Thiocolchicoside IP 4 mg

This combination is used to treat pain associated with muscle spasm


  • Pain after dental surgery
  • Muscle stiffness
  • Osteoarthritis
  • Rheumatoid arthritis

About Composition


Lornoxicam belongs to the class of non- steroidal anti-inflammatory drugs. It shows analgesic, antipyretic , anti-inflammatory properties. It act as potent inhibitor of prostaglandin synthesis.


Thiocolchicoside is the semi-synthetic derivative of colchicine . it is used as muscle relaxant and also have anti- inflammatory property, analgesic property. It is obtained from the seed of plant Superba gloriosa.

Mechanism of Action


It inhibits the synthesis of prostaglandins and thromboxanes synthesis by inhibiting the enzyme cox-1 and cox-2.


Thiocolchicine mediates its effect by binding with the GABA receptor which is inhibitory neurotransmitter and activate it. It also activates the glycine receptors and prevents the muscle contraction by activating the GABA and promotes muscle relaxation.



Absorption- It is orally absorbed from the GIT
Protein binding- Lornoxicam is mainly bound to albumin i.e upto 99.9%
Metabolism- Lornoxicam is converted into 5-hydroxy lornoxicam
Excretion- It is excreted via urine


Absorption- It is orally absorbed.
Plasma proteins- It is bound to serum protein i.e albumin
Metabolism- It metabolized to active and inactive metabolites i.e 3-demethylcolchicine, 3-O-glucurono-demethylcolchicine (active metabolite) or didemethylcolchicine (inactive metabolite)
Excretion- Excretion takes via urine and feces

Side Effects

  • Nausea
  • Vomiting
  • Diarrhea
  • Stomachache
  • Indigestion


  • Contraindicated in patients with known hypersensitivity
  • Contraindicated in pregnant women
  • Contraindicated in GI tract bleeding
  • Contraindicated in hepatic and renal failure
Know About new DCGI Approved Products